Alternatively, SF might be used in place of conventional ligand-activation based therapeutic strategies to stimulate EGFR signaling in diabetes-induced cardiac dysfunction which results from depressed EGFR-ERK1/2 phosphorylation [34]. The gene discussed is MAPK3; the disease is diabetes mellitus.